|
AP3B1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.93010002109185E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.73569999484258E-08 |
| Normal-vs-Stage2 |
2.283800E-02 |
| Normal-vs-Stage3 |
7.62520000474609E-08 |
| Normal-vs-Stage4 |
8.11489986318747E-10 |
| Stage1-vs-Stage2 |
3.592300E-02 |
| Stage1-vs-Stage3 |
2.805000E-01 |
| Stage1-vs-Stage4 |
2.641900E-02 |
| Stage2-vs-Stage3 |
1.856140E-02 |
| Stage2-vs-Stage4 |
3.259800E-03 |
| Stage3-vs-Stage4 |
3.194000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.05910002779331E-09 |
| Normal-vs-AfricanAmerican |
1.799880E-02 |
| Normal-vs-Asian |
3.09519999630581E-08 |
| Caucasian-vs-AfricanAmerican |
1.372620E-01 |
| Caucasian-vs-Asian |
2.564800E-01 |
| AfricanAmerican-vs-Asian |
3.403900E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.35880000046762E-07 |
| Normal-vs-Female |
9.30569998836006E-09 |
| Male-vs-Female |
9.994400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.27820000431711E-08 |
| Normal-vs-Age(41-60Yrs) |
5.70209999994908E-07 |
| Normal-vs-Age(61-80Yrs) |
1.66710000026882E-07 |
| Normal-vs-Age(81-100Yrs) |
1.629510E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.766600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.220000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.414800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.292800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.091800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.917200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.658410E-03 |
| Classical-VS-Follicular |
7.426000E-01 |
| Classical-VS-Other |
3.018200E-01 |
| Classical-VS-Normal |
1.55319999972647E-07 |
| Tall-VS-Follicular |
5.280100E-03 |
| Tall-VS-Other |
8.074600E-01 |
| Tall-VS-Normal |
7.31799953967993E-10 |
| Follicular-VS-Other |
3.209200E-01 |
| Follicular-VS-Normal |
1.229660E-04 |
| Other-VS-Normal |
2.763300E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.79869999997295E-06 |
| Normal-vs-N1 |
1.47939993588864E-10 |
| N0-vs-N1 |
3.235400E-03 |
|
|
